Roche Presents New Data on Vabysmo at EURETINA
Roche announced new data from the VOYAGER study evaluating Vabysmo (faricimab) in neovascular age-related macular degeneration, diabetic macular edema, and macular edema. The data highlighted the drug's effectiveness, durability, and safety in real-world conditions.